You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSolifenacin
Accession NumberDB01591  (APRD00168)
TypeSmall Molecule
GroupsApproved
DescriptionSolifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
Structure
Thumb
SynonymsNot Available
External Identifiers
  • YM-67905
  • YM-905
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Solifenacintablet5 mgoralActavis Pharma Company2015-09-30Not applicableCanada
Act Solifenacintablet10 mgoralActavis Pharma Company2015-09-30Not applicableCanada
Auro-solifenacintablet5 mgoralAuro Pharma Inc2016-01-04Not applicableCanada
Auro-solifenacintablet10 mgoralAuro Pharma Inc2016-01-04Not applicableCanada
Jamp-solifenacintablet10 mgoralJamp Pharma Corporation2015-12-29Not applicableCanada
Jamp-solifenacintablet5 mgoralJamp Pharma Corporation2015-12-29Not applicableCanada
Med-solifenacintablet5 mgoralGeneric Medical Partners Inc2016-04-18Not applicableCanada
Med-solifenacintablet10 mgoralGeneric Medical Partners Inc2016-04-18Not applicableCanada
Mint-solifenacintablet5 mgoralMint Pharmaceuticals Inc2016-04-20Not applicableCanada
Mint-solifenacintablet10 mgoralMint Pharmaceuticals Inc2016-04-20Not applicableCanada
PMS-solifenacintablet10 mgoralPharmascience Inc2015-10-28Not applicableCanada
PMS-solifenacintablet5 mgoralPharmascience Inc2015-10-28Not applicableCanada
Ran-solifenacintablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.2015-12-29Not applicableCanada
Ran-solifenacintablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2015-12-29Not applicableCanada
Sandoz Solifenacintablet10 mgoralSandoz Canada Incorporated2015-09-30Not applicableCanada
Sandoz Solifenacintablet10 mgoralSandoz Canada Incorporated2015-09-30Not applicableCanada
Sandoz Solifenacintablet5 mgoralSandoz Canada Incorporated2015-09-30Not applicableCanada
Sandoz Solifenacintablet5 mgoralSandoz Canada Incorporated2015-09-30Not applicableCanada
Solifenacin Succinatetablet5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Solifenacin Succinatetablet10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Solifenacin Succinate Tabletstablet5 mgoralMda Inc.Not applicableNot applicableCanada
Solifenacin Succinate Tabletstablet10 mgoralMda Inc.Not applicableNot applicableCanada
Teva-solifenacintablet10 mgoralTeva Canada Limited2015-07-30Not applicableCanada
Teva-solifenacintablet5 mgoralTeva Canada Limited2015-07-30Not applicableCanada
Vesicaretablet, film coated10 mg/1oralCardinal Health2005-01-05Not applicableUs
Vesicaretablet, film coated5 mg/1oralAstellas Pharma Technologies, Inc.2005-01-05Not applicableUs
Vesicaretablet, film coated5 mg/1oralCardinal Health2005-01-05Not applicableUs
Vesicaretablet5 mgoralAstellas Pharma Canada Inc2006-06-23Not applicableCanada
Vesicaretablet, film coated10 mg/1oralAstellas Pharma Technologies, Inc.2005-01-05Not applicableUs
Vesicaretablet, film coated10 mg/1oralCardinal Health2005-01-05Not applicableUs
Vesicaretablet10 mgoralAstellas Pharma Canada Inc2006-06-23Not applicableCanada
Vesicaretablet, film coated10 mg/1oralPhysicians Total Care, Inc.2007-09-13Not applicableUs
Vesicaretablet, film coated5 mg/1oralCardinal Health2005-01-05Not applicableUs
Vesicaretablet, film coated5 mg/1oralPhysicians Total Care, Inc.2005-08-29Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VesikurNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Solifenacin hydrochloride
Thumb
  • InChI Key: YAUBKMSXTZQZEB-VROPFNGYSA-N
  • Monoisotopic Mass: 398.1761058
  • Average Mass: 398.93
DBSALT001640
Solifenacin succinate
242478-38-2
Thumb
  • InChI Key: RXZMMZZRUPYENV-VROPFNGYSA-N
  • Monoisotopic Mass: 480.226036766
  • Average Mass: 480.5528
DBSALT001639
Categories
UNIIA8910SQJ1U
CAS number242478-37-1
WeightAverage: 362.473
Monoisotopic: 362.199428085
Chemical FormulaC23H26N2O2
InChI KeyFBOUYBDGKBSUES-VXKWHMMOSA-N
InChI
InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
IUPAC Name
(3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
SMILES
O=C(O[[email protected]]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
PharmacodynamicsSolifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.
Mechanism of actionSolifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of incontinence episodes.
Related Articles
AbsorptionThe absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
Volume of distribution
  • 600 L
Protein bindingSolifenacin is approximately 98% (in vivo) bound to human plasma proteins, principally to alpha1-acid glycoprotein.
Metabolism

Solifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist. The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing.

SubstrateEnzymesProduct
Solifenacin
Not Available
4R-hydroxy solifenacinDetails
Solifenacin
Not Available
4R-hydroxy-N-oxide solifenacinDetails
Route of eliminationThe primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist.
Half lifeThe elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.
ClearanceNot Available
ToxicityOverdosage with solifenacin can potentially result in severe anticholinergic effects and should be treated accordingly. The highest solifenacin dose given to human volunteers was a single 100 mg dose. Intolerable anticholinergic side effects (fixed and dilated pupils, blurred vision, failure of heel-to-toe exam, tremors and dry skin) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9706
Blood Brain Barrier+0.6159
Caco-2 permeable-0.6679
P-glycoprotein substrateSubstrate0.7801
P-glycoprotein inhibitor IInhibitor0.8572
P-glycoprotein inhibitor IIInhibitor0.8611
Renal organic cation transporterNon-inhibitor0.7498
CYP450 2C9 substrateNon-substrate0.8311
CYP450 2D6 substrateNon-substrate0.7264
CYP450 3A4 substrateSubstrate0.545
CYP450 1A2 substrateNon-inhibitor0.8445
CYP450 2C9 inhibitorNon-inhibitor0.8755
CYP450 2D6 inhibitorNon-inhibitor0.8593
CYP450 2C19 inhibitorNon-inhibitor0.7037
CYP450 3A4 inhibitorNon-inhibitor0.7027
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8748
Ames testNon AMES toxic0.8871
CarcinogenicityNon-carcinogens0.9596
BiodegradationNot ready biodegradable0.9828
Rat acute toxicity2.3839 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8115
hERG inhibition (predictor II)Inhibitor0.727
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral5 mg
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Prices
Unit descriptionCostUnit
Fer-In-Sol 75 (15 Fe)mg/ml Solution 50ml Bottle19.0USD bottle
Fergon 100 240 (27 Fe)mg tablet Bottle15.99USD bottle
Fortabs 50-325-40 mg tablet0.4USD tablet
Hemocyte tablet0.33USD tablet
Hemocyte-f tablet0.33USD tablet
Feosol 45 mg tablet0.31USD tablet
Slow fe 142 mg tablet0.27USD tablet
Ferrous fumarate 324 mg tablet0.21USD tablet
Fer-in-sol 15 mg/ml drops0.19USD ml
Feosol 65 mg tablet0.18USD tablet
Ferretts 325 mg tablet0.14USD tablet
Fergon 27 mg tablet0.05USD tablet
Ferretts ips liquid0.05USD ml
Ferrous gluc 246 mg (27 mg) tablet0.04USD tablet
Ferrous gluconate 27 mg tablet0.04USD tablet
Ferrous sulfate 28 mg tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2208839 No2006-01-312015-12-27Canada
US6017927 No1998-11-192018-11-19Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0729 mg/mLALOGPS
logP3.9ALOGPS
logP3.96ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)8.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity106.06 m3·mol-1ChemAxon
Polarizability40.13 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Katsumi Saito, Masataka Katsuma, “Solifenacin transdermal preparation and method for enhancing transdermal permeation thereof.” U.S. Patent US20050181031, issued August 18, 2005.

US20050181031
General ReferencesNot Available
External Links
ATC CodesG04CA53G04BD08
AHFS Codes
  • 86:12.00
PDB EntriesNot Available
FDA labelDownload (68.6 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with 1,10-Phenanthroline.
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Solifenacin can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Solifenacin can be decreased when combined with 2-mercaptobenzothiazole.
AclidiniumAclidinium may increase the anticholinergic activities of Solifenacin.
AclidiniumThe risk or severity of adverse effects can be increased when Solifenacin is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Solifenacin is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Solifenacin is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Ambenonium.
AmiodaroneThe metabolism of Solifenacin can be decreased when combined with Amiodarone.
AmiodaroneSolifenacin may increase the QTc-prolonging activities of Amiodarone.
AmorolfineThe metabolism of Solifenacin can be decreased when combined with Amorolfine.
Amphotericin BThe metabolism of Solifenacin can be decreased when combined with Amphotericin B.
AN2690The metabolism of Solifenacin can be decreased when combined with AN2690.
AnagrelideSolifenacin may increase the QTc-prolonging activities of Anagrelide.
AnidulafunginThe metabolism of Solifenacin can be decreased when combined with Anidulafungin.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Solifenacin.
AprepitantThe serum concentration of Solifenacin can be increased when it is combined with Aprepitant.
Arsenic trioxideSolifenacin may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Solifenacin can be decreased when combined with Artemether.
ArtemetherSolifenacin may increase the QTc-prolonging activities of Artemether.
AsenapineSolifenacin may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Solifenacin can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Solifenacin can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Solifenacin.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Solifenacin.
AzithromycinSolifenacin may increase the QTc-prolonging activities of Azithromycin.
Bafilomycin A1The metabolism of Solifenacin can be decreased when combined with Bafilomycin A1.
BedaquilineSolifenacin may increase the QTc-prolonging activities of Bedaquiline.
BenactyzineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Solifenacin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Solifenacin.
Benzoic AcidThe metabolism of Solifenacin can be decreased when combined with Benzoic Acid.
BexaroteneThe serum concentration of Solifenacin can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Solifenacin is combined with Bezitramide.
BifonazoleThe metabolism of Solifenacin can be decreased when combined with Bifonazole.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Solifenacin.
BoceprevirThe metabolism of Solifenacin can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Solifenacin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Solifenacin can be decreased when it is combined with Bosentan.
Botulinum Toxin Type ASolifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BSolifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Buprenorphine.
ButenafineThe metabolism of Solifenacin can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Solifenacin can be decreased when combined with Butoconazole.
ButorphanolThe risk or severity of adverse effects can be increased when Solifenacin is combined with Butorphanol.
CandicidinThe metabolism of Solifenacin can be decreased when combined with Candicidin.
CarbamazepineThe metabolism of Solifenacin can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Solifenacin is combined with Carfentanil.
CaspofunginThe metabolism of Solifenacin can be decreased when combined with Caspofungin.
CeritinibThe serum concentration of Solifenacin can be increased when it is combined with Ceritinib.
CeritinibSolifenacin may increase the QTc-prolonging activities of Ceritinib.
CeruleninThe metabolism of Solifenacin can be decreased when combined with Cerulenin.
ChloroquineSolifenacin may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Solifenacin.
ChloroxineThe metabolism of Solifenacin can be decreased when combined with Chloroxine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Chlorphenoxamine.
ChlorpromazineSolifenacin may increase the QTc-prolonging activities of Chlorpromazine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Solifenacin.
CiclopiroxThe metabolism of Solifenacin can be decreased when combined with Ciclopirox.
CimetropiumSolifenacin may increase the anticholinergic activities of Cimetropium.
CiprofloxacinSolifenacin may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideSolifenacin may increase the QTc-prolonging activities of Cisapride.
CitalopramSolifenacin may increase the QTc-prolonging activities of Citalopram.
ClarithromycinSolifenacin may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Solifenacin can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Solifenacin can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Solifenacin can be decreased when combined with Clotrimazole.
ClozapineSolifenacin may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Solifenacin can be decreased when combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Codeine.
ConivaptanThe serum concentration of Solifenacin can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Coumaphos.
CrizotinibSolifenacin may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Solifenacin can be decreased when combined with Crizotinib.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Solifenacin.
CyclosporineThe metabolism of Solifenacin can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Solifenacin can be decreased when it is combined with Dabrafenib.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Solifenacin.
DarunavirThe metabolism of Solifenacin can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Solifenacin can be increased when it is combined with Dasatinib.
DecamethoniumThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Decamethonium.
Decanoic AcidThe metabolism of Solifenacin can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Solifenacin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Solifenacin can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Solifenacin.
DexamethasoneThe serum concentration of Solifenacin can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Solifenacin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Solifenacin can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydromorphine.
DiltiazemThe metabolism of Solifenacin can be decreased when combined with Diltiazem.
DiphenoxylateThe risk or severity of adverse effects can be increased when Solifenacin is combined with Diphenoxylate.
DisopyramideSolifenacin may increase the QTc-prolonging activities of Disopyramide.
DofetilideSolifenacin may increase the QTc-prolonging activities of Dofetilide.
DolasetronSolifenacin may increase the QTc-prolonging activities of Dolasetron.
DomperidoneSolifenacin may increase the QTc-prolonging activities of Domperidone.
DonepezilThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Donepezil.
DoxycyclineThe metabolism of Solifenacin can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Solifenacin is combined with DPDPE.
DronabinolSolifenacin may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Solifenacin can be decreased when combined with Dronedarone.
DronedaroneSolifenacin may increase the QTc-prolonging activities of Dronedarone.
DroperidolSolifenacin may increase the QTc-prolonging activities of Droperidol.
EchothiophateThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Echothiophate.
EconazoleThe metabolism of Solifenacin can be decreased when combined with Econazole.
EdrophoniumThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of Solifenacin can be decreased when it is combined with Efavirenz.
EfinaconazoleThe metabolism of Solifenacin can be decreased when combined with Efinaconazole.
EliglustatSolifenacin may increase the QTc-prolonging activities of Eliglustat.
EluxadolineSolifenacin may increase the constipating activities of Eluxadoline.
EnzalutamideThe serum concentration of Solifenacin can be decreased when it is combined with Enzalutamide.
ErythromycinSolifenacin may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Solifenacin can be decreased when combined with Erythromycin.
EscitalopramSolifenacin may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Solifenacin can be decreased when it is combined with Eslicarbazepine acetate.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Solifenacin.
EthylmorphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Etorphine.
EtravirineThe serum concentration of Solifenacin can be decreased when it is combined with Etravirine.
FentanylThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fentanyl.
FenthionThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fesoterodine.
FlecainideSolifenacin may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Solifenacin can be decreased when combined with Fluconazole.
FlucytosineThe metabolism of Solifenacin can be decreased when combined with Flucytosine.
FluoxetineSolifenacin may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolSolifenacin may increase the QTc-prolonging activities of Flupentixol.
FluvoxamineThe metabolism of Solifenacin can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Solifenacin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Solifenacin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Solifenacin can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Solifenacin can be increased when it is combined with Fusidic Acid.
Gadobenic acidSolifenacin may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Solifenacin.
GemifloxacinSolifenacin may increase the QTc-prolonging activities of Gemifloxacin.
Ginkgo bilobaThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Solifenacin is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Solifenacin.
GlycopyrroniumSolifenacin may increase the anticholinergic activities of Glycopyrronium.
GlyphosateThe metabolism of Solifenacin can be decreased when combined with Glyphosate.
GoserelinSolifenacin may increase the QTc-prolonging activities of Goserelin.
GranisetronSolifenacin may increase the QTc-prolonging activities of Granisetron.
GriseofulvinThe metabolism of Solifenacin can be decreased when combined with Griseofulvin.
HaloperidolSolifenacin may increase the QTc-prolonging activities of Haloperidol.
HaloproginThe metabolism of Solifenacin can be decreased when combined with Haloprogin.
HeroinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hexamethonium.
HexetidineThe metabolism of Solifenacin can be decreased when combined with Hexetidine.
HomatropineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Solifenacin.
HydrocodoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Solifenacin.
HydromorphoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Solifenacin.
IbutilideSolifenacin may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Solifenacin can be increased when it is combined with Idelalisib.
IloperidoneSolifenacin may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Solifenacin can be decreased when combined with Imatinib.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Solifenacin.
IndinavirThe metabolism of Solifenacin can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Solifenacin.
IsavuconazoniumThe metabolism of Solifenacin can be decreased when combined with Isavuconazonium.
IsoconazoleThe metabolism of Solifenacin can be decreased when combined with Isoconazole.
IsoflurophateThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Isoflurophate.
IsradipineThe metabolism of Solifenacin can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Solifenacin.
ItraconazoleThe metabolism of Solifenacin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Solifenacin can be increased when it is combined with Ivacaftor.
KetobemidoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Ketobemidone.
KetoconazoleThe metabolism of Solifenacin can be decreased when combined with Ketoconazole.
LenvatinibSolifenacin may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideSolifenacin may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinSolifenacin may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Solifenacin is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Solifenacin is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Solifenacin is combined with Lofentanil.
LopinavirThe metabolism of Solifenacin can be decreased when combined with Lopinavir.
LopinavirSolifenacin may increase the QTc-prolonging activities of Lopinavir.
LovastatinThe metabolism of Solifenacin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Solifenacin can be increased when it is combined with Luliconazole.
LumefantrineSolifenacin may increase the QTc-prolonging activities of Lumefantrine.
MalathionThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Solifenacin.
MefloquineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Solifenacin is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Solifenacin.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.
MetixeneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Solifenacin.
MevastatinThe metabolism of Solifenacin can be decreased when combined with Mevastatin.
MianserinMianserin may increase the anticholinergic activities of Solifenacin.
MicafunginThe metabolism of Solifenacin can be decreased when combined with Micafungin.
MiconazoleThe metabolism of Solifenacin can be decreased when combined with Miconazole.
MifepristoneThe metabolism of Solifenacin can be decreased when combined with Mifepristone.
MifepristoneSolifenacin may increase the QTc-prolonging activities of Mifepristone.
MiltefosineThe metabolism of Solifenacin can be decreased when combined with Miltefosine.
MinaprineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Solifenacin is combined with Mirabegron.
MitotaneThe serum concentration of Solifenacin can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Solifenacin can be decreased when it is combined with Modafinil.
MonensinThe metabolism of Solifenacin can be decreased when combined with Monensin.
MorphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Morphine.
MoxifloxacinSolifenacin may increase the QTc-prolonging activities of Moxifloxacin.
MyxothiazolThe metabolism of Solifenacin can be decreased when combined with Myxothiazol.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Solifenacin is combined with N-butylscopolammonium bromide.
NabiloneSolifenacin may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Solifenacin can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Solifenacin can be decreased when combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Nalbuphine.
NatamycinThe metabolism of Solifenacin can be decreased when combined with Natamycin.
NefazodoneThe metabolism of Solifenacin can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Solifenacin can be decreased when combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Solifenacin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Solifenacin can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Solifenacin can be decreased when combined with Nilotinib.
NilotinibSolifenacin may increase the QTc-prolonging activities of Nilotinib.
NitroxolineThe metabolism of Solifenacin can be decreased when combined with Nitroxoline.
NormethadoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Solifenacin is combined with NVA237.
NystatinThe metabolism of Solifenacin can be decreased when combined with Nystatin.
OfloxacinSolifenacin may increase the QTc-prolonging activities of Ofloxacin.
OlaparibThe metabolism of Solifenacin can be decreased when combined with Olaparib.
OndansetronSolifenacin may increase the QTc-prolonging activities of Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Solifenacin is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Solifenacin.
OsimertinibThe serum concentration of Solifenacin can be increased when it is combined with Osimertinib.
OxiconazoleThe metabolism of Solifenacin can be decreased when combined with Oxiconazole.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Solifenacin.
OxycodoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Solifenacin.
pafuramidineThe metabolism of Solifenacin can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Solifenacin can be increased when it is combined with Palbociclib.
PaliperidoneSolifenacin may increase the QTc-prolonging activities of Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Solifenacin.
PanobinostatSolifenacin may increase the QTc-prolonging activities of Panobinostat.
PazopanibSolifenacin may increase the QTc-prolonging activities of Pazopanib.
PentamidineThe metabolism of Solifenacin can be decreased when combined with Pentamidine.
PentamidineSolifenacin may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pentazocine.
PentobarbitalThe metabolism of Solifenacin can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Solifenacin.
PerflutrenSolifenacin may increase the QTc-prolonging activities of Perflutren.
PethidineThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pethidine.
PhenobarbitalThe metabolism of Solifenacin can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Solifenacin can be increased when combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Physostigmine.
PimozideSolifenacin may increase the QTc-prolonging activities of Pimozide.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Solifenacin.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Solifenacin.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Solifenacin.
PosaconazoleThe metabolism of Solifenacin can be decreased when combined with Posaconazole.
Potassium ChlorideSolifenacin may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Solifenacin.
PrimaquineSolifenacin may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Solifenacin can be increased when combined with Primidone.
ProcainamideSolifenacin may increase the QTc-prolonging activities of Procainamide.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Solifenacin.
PromazineSolifenacin may increase the QTc-prolonging activities of Promazine.
PropafenoneSolifenacin may increase the QTc-prolonging activities of Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Solifenacin.
PyridostigmineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Pyridostigmine.
QuetiapineSolifenacin may increase the QTc-prolonging activities of Quetiapine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Solifenacin.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Solifenacin.
QuinineSolifenacin may increase the QTc-prolonging activities of Quinine.
RadicicolThe metabolism of Solifenacin can be decreased when combined with Radicicol.
RamosetronSolifenacin may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Solifenacin can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Solifenacin is combined with Remifentanil.
RifabutinThe metabolism of Solifenacin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Solifenacin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Solifenacin can be increased when combined with Rifapentine.
RitonavirThe metabolism of Solifenacin can be decreased when combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Rivastigmine.
Salicylhydroxamic AcidThe metabolism of Solifenacin can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidThe metabolism of Solifenacin can be decreased when combined with Salicylic acid.
SaquinavirSolifenacin may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Solifenacin can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Solifenacin is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Solifenacin.
SertaconazoleThe metabolism of Solifenacin can be decreased when combined with Sertaconazole.
SildenafilThe metabolism of Solifenacin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Solifenacin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Solifenacin can be increased when it is combined with Simeprevir.
SinefunginThe metabolism of Solifenacin can be decreased when combined with Sinefungin.
SirolimusThe metabolism of Solifenacin can be decreased when combined with Sirolimus.
SotalolSolifenacin may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Solifenacin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Solifenacin can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.
SulconazoleThe metabolism of Solifenacin can be decreased when combined with Sulconazole.
SulfisoxazoleSolifenacin may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Solifenacin can be decreased when combined with Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Solifenacin.
TacrineThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Solifenacin is combined with Tapentadol.
TavaboroleThe metabolism of Solifenacin can be decreased when combined with Tavaborole.
TelaprevirThe metabolism of Solifenacin can be decreased when combined with Telaprevir.
TelavancinSolifenacin may increase the QTc-prolonging activities of Telavancin.
TelithromycinSolifenacin may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Solifenacin can be decreased when combined with Telithromycin.
TerbinafineThe metabolism of Solifenacin can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Solifenacin can be decreased when combined with Terconazole.
TetrabenazineSolifenacin may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineSolifenacin may increase the QTc-prolonging activities of Thioridazine.
ThymolThe metabolism of Solifenacin can be decreased when combined with Thymol.
TiclopidineThe metabolism of Solifenacin can be decreased when combined with Ticlopidine.
TioconazoleThe metabolism of Solifenacin can be decreased when combined with Tioconazole.
TiotropiumSolifenacin may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Solifenacin.
TocilizumabThe serum concentration of Solifenacin can be decreased when it is combined with Tocilizumab.
TolnaftateThe metabolism of Solifenacin can be decreased when combined with Tolnaftate.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Solifenacin.
TopiramateThe risk or severity of adverse effects can be increased when Solifenacin is combined with Topiramate.
ToremifeneSolifenacin may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Solifenacin is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Solifenacin.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Solifenacin.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Solifenacin.
TrimetrexateThe metabolism of Solifenacin can be decreased when combined with Trimetrexate.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Solifenacin.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Solifenacin.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Solifenacin.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Solifenacin.
UmeclidiniumThe risk or severity of adverse effects can be increased when Solifenacin is combined with Umeclidinium.
VandetanibSolifenacin may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Solifenacin.
VemurafenibSolifenacin may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Solifenacin can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Solifenacin can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Solifenacin can be decreased when combined with Voriconazole.
ZiprasidoneThe metabolism of Solifenacin can be decreased when combined with Ziprasidone.
ZiprasidoneSolifenacin may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolSolifenacin may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545 ]
  4. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  5. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  4. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605 ]
  2. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:15